Second European Matchmaking Event on the Development and Production of COVID-19 Therapeutics
We invite all clusters to inform their companies about this matchmaking opportunity!
Building on the experience of the European Union (EU) Task Force for Industrial Scale-up of COVID-19 vaccines and therapeutics, the European Commission (EC) continues to facilitate cooperation between actors in the EU supply chain to ensure that available therapeutics are produced in sufficient quantity as soon as possible. To support the industry, the Commission organises the Second Virtual Matchmaking Event on COVID-19 Therapeutics, which aims to accelerate:
- The development of new and repurposed medicines for COVID-19 therapeutics, i.e. medicines specifically developed for an indication in treatment of COVID-19, at all stages of COVID-19 disease;
- The development of medicines used to treat the symptoms of COVID-19;
- The production of disposable materials (e.g. single use systems), ingredients and raw materials required for the manufacture of medicinal products; and
- Mobilise the EU pharma manufacturing capacity for the production of medicines to treat or prevent COVID-19.
The event will take place virtually (through B2Match) on the 29th November (Monday) and 30th November (Tuesday) 2021, in partnership with the Council of European BioRegions (CEBR) and the European Clusters Alliance (ECA).
The target group of this event is the entire EU COVID-19 therapeutics supply chain having development and/or production facilities in the EU. The event is open to EU companies and non-EU companies with research/production facilities in the European Union Member States (including companies in the portfolio of 10 most promising treatments COVID-19 Therapeutics Strategy (europa.eu).
Companies interested in participating in the event must complete the registration form by 18 November 2021 (23h59 CET).